The purpose of the present invention is to provide a novel compound which is useful for the suppression of TGF-β signaling, the treatment or prevention of fibrosis, obesity and diabetes, the suppression of cancer metastasis, and the enhancement of antitumor immunity. Provided is a compound represented by formula (1) [wherein X represents an oxygen atom, a sulfur atom, or the like; Y represents a carbonyl group, a thiocarbonyl group, a sulfoxide group, or a sulfonyl group; R1represents a lower alkyl group which may have a substituent, or the like; R2represents a hydrogen atom, or the like; R3represents a hydrogen atom, or the like; R4represents a hydrogen atom, or the like; and R5 represents a hydrogen atom, or the like] or a salt thereof.
C07D 311/14 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 6 and unsubstituted in position 7
A61K 31/453 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
A61K 31/4433 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
C07D 335/02 - Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 407/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 407/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 407/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07H 13/12 - Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group —X—C (=X)—X—, or halides thereof, in which X means nitrogen, oxygen, sulfur, selenium, or tellurium, e.g. carbonic acid, carbamic acid
Provided is a combination therapy for an antitumor agent that exhibits a high antitumor effect using a pyridone carboxylic acid derivative. An antitumor agent characterized by being administered in combination with other antitumor agents, and comprising, as an active ingredient, a compound represented by the formula (1) (in the formula, the wavy line represents the steric configuration being the R configuration or the S configuration) or a salt thereof, wherein the other antitumor agents are one or more types selected from cytarabine, venetoclax, azacitidine, gilteritinib, birabresib, vorinostat, GSK126, MK-8776, AZD7762, rabusertib, dabrafenib, vemurafenib, olaparib, adavosertib, alisertib, decitabine, midostaurin, and AZD5991.
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4535 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A method for activating or enhancing expression of sirtuins or Klotho, including administering S-1-propenylcysteine or a salt thereof to an animal in need thereof. A method for increasing NAD+, including administering S-1-propenylcysteine or a salt thereof to an animal in need thereof. A method for suppressing senescent cells, including administering S-1-propenylcysteine or a salt thereof to an animal in need thereof.
A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
4.
SIRTUIN ACTIVATOR OR EXPRESSION ENHANCER, NAD+ INCREASING AGENT, AND SENESCENT CELL INHIBITOR
Provided is a novel use of a composition that contains a prescribed sulfur-containing compound, a salt thereof, or both. The present invention is a sirtuin activator or expression enhancer, a NAD+ increasing agent, or a senescent cell inhibitor containing, as an active ingredient, a compound (excluding S-1-propenylcysteine) represented by general formula 1A or 1B, or a salt thereof.
A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
A61K 31/54 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 43/00 - Drugs for specific purposes, not provided for in groups
5.
eNAMPT INCREASING AGENT, SIRTUIN ACTIVATION OR EXPRESSION ENHANCER, NAD+ INCREASING AGENT, AND SENESCENT CELL INHIBITOR
Provided is a novel use of a composition that contains S-1-propenyl cysteine and/or a salt thereof. The present invention can be an eNAMPT increasing agent in which S-1-propenyl cysteine or a salt thereof is an active ingredient. The present invention can be an eNAMPT increasing agent that contains S-1-propenyl cysteine or a salt thereof and that is administered to an animal. Particularly, it is preferable that the present invention be used for increasing eNAMPT in blood.
Provided is a novel use of S-1-propenylcysteine, a salt thereof or a composition containing the same. A Sirtuin or Klotho activator or expression enhancer that comprises S-1-propenylcysteine or a salt thereof as an active ingredient.
Provided is a medicine or food useful for preventing, ameliorating or treating periodontal disease. An agent for preventing, ameliorating or treating periodontal disease comprises one or more cysteine derivatives selected from the group consisting of S1PC, SAC and SAMC or a salt thereof as an active ingredient.
To provide a compound used for activating autophagy, which has few side effects and mild effects comprising S1PC or a salt thereof as an active ingredient.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations; Chinese herbs for medicinal
purposes; reagent paper for medical purposes; adhesive tapes
for medical purposes; gauze for dressing; compresses;
capsules for medicines; eyepatches for medical purposes;
sanitary tampons; sanitary pads; sanitary panties; absorbent
cotton; adhesive plasters; bandages for dressings;
breast-nursing pads; cotton swabs for medical purposes;
teeth filling material; babies' diapers; napkins for
incontinents; fly catching paper; mothproofing paper;
lacteal flour for babies; nutritional supplements; dietary
supplements for animals; dietetic beverages adapted for
medical purposes; dietetic foods adapted for medical
purposes; food for babies; nutraceutical preparations for
therapeutic or medical purposes; semen for artificial
insemination; ointments for pharmaceutical purposes;
pharmaceutical preparations for skin care; lotions for
pharmaceutical purposes; tonics [medicine]; medicinal
drinks; germicides; air purifying preparations.
10.
AGENT FOR PREVENTING, AMELIORATING, OR TREATING PERIODONTAL DISEASE
Provided is a pharmaceutical or food useful for preventing, ameliorating, or treating periodontal disease. An agent for preventing, ameliorating, or treating periodontal disease comprising, as an active ingredient, at least one cysteine derivative selected from S1PC, SAC, and SAMC or a salt thereof.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations in the nature of anti-tussive expectorants, analgesics, anti-inflammatories, eye drops, and topical dermatological preparations for the treatment of gastrointestinal diseases, colds, rhinitis, hemorrhoids, dermatitis and eczema; Chinese traditional medicinal herbs; reagent paper for medical purposes; adhesive tapes for medical purposes; gauze for dressings; medicated compresses; capsules sold empty for pharmaceuticals; eyepatches for medical purposes; sanitary tampons; sanitary pads; sanitary panties; absorbent cotton for medical purposes; adhesive plasters for medical purposes; bandages for dressings; breast-nursing pads; cotton swabs for medical purposes; teeth filling material; babies' diapers; napkins for incontinents; fly catching paper; mothproofing paper; lacteal flour for babies; nutritional supplements; dietary supplements for animals; dietetic beverages adapted for medical purposes; dietetic foods adapted for medical purposes; food for babies; nutraceutical preparations for use as a dietary supplement; semen for artificial insemination; medicated ointments for pharmaceutical purposes, namely, treating dermatological conditions, hemorrhoids, athlete's foot and ringworm; pharmaceutical preparations for skin care; lotions for pharmaceutical purposes, namely, pharmaceutical skin lotions; Medicinal tonics, namely, medicinal drinks; germicides; air purifying preparations
Provided is a blood flow improver which is safe and has a mild action. The blood flow improver comprises S-1-propenylcysteine or a salt thereof as an active ingredient.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
Provided is a compound which has little adverse side effects and a mild action and can be used for the activation of autophagy. An autophagy activating agent which contains S1PC or a salt thereof as an active ingredient.
A61K 36/8962 - Allium, e.g. garden onion, leek, garlic or chives
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/14 - Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Provided is a blood flow improver which is safe and has a mild action. This blood flow improver comprises S-1-propenylcysteine or a salt thereof as an active ingredient.
Provided is a novel compound which has high antitumor activity, while having low toxicity to normal cells. A pyridone carboxylic acid derivative represented by formula (1) or a salt thereof. (In the formula, R1 represents a hydrogen atom, a halogen atom or the like; R2 represents a hydrogen atom, a halogen atom or the like; each of R3-R6 represents a hydrogen atom or the like; R7 represents a hydrogen atom or the like; R8 represents a hydrogen atom, a halogen atom, a group represented by formula (a) (wherein each of Ra1 and Ra2 represents a hydrogen atom, a hydroxy group, an optionally substituted lower alkyl group or the like) or the like; or alternatively, R7 and R8 combine with each other to represent =N-OR10 (wherein R10 represents a hydrogen atom, an optionally substituted lower alkyl group or an aralkyl group) or R7, R8 and the adjacent carbon atom combine with each other to represent an optionally substituted 4-6 membered saturated heterocyclic ring, or the like; R9 represents a hydrogen atom or the like; X represents a nitrogen atom or the like; and Y represents a nitrogen atom or the like.)
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61P 35/02 - Antineoplastic agents specific for leukemia
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
Provided is an antihypertensive agent that is safe and has a mild effect.
An antihypertensive agent comprising S-1-propenylcysteine or a salt thereof as an active ingredient.
An immunomodulator useful for modulating immune function and maintaining intravital homeostasis is provided. The immunomodulator comprises S-1-propenycysteine or a salt thereof as an active ingredient.
Provided are a novel pyridonecarboxylic acid derivative which is highly effective even against bacteria such as methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa, and Clostridium difficile, and is less likely to be affected by a drug efflux pump, or a salt thereof, and an antibacterial agent containing the pyridonecarboxylic acid derivative or a salt thereof. The pyridonecarboxylic acid derivative is represented by formula (1): (in the formula, R1 represents a hydrogen atom, a halogen atom, a lower alkyl group, or an amino group; R2 represents radical-NH-R6 (here, R6 represents a hydrogen atom, a lower alkyl group, an amino lower alkyl group, etc.), radical-O-R7 (here, R7 represents a hydrogen atom, a lower alkyl group, etc.), radical-(CH2)m-R8 (here, R8 represents an amino group, etc., m represents an integer of 1-4), or a cyclic amino group represented by formula (2): (in the formula, Y represents NH or C-R9aR9b (here, R9a and R9b each independently represent a hydrogen atom, a lower alkyl group, an amino group, a lower alkylamino group, etc.), and n and p are an integer of 1 or 2); R3 represents a hydrogen atom, a halogen atom, a lower alkyl group, etc.; R4 represents a hydrogen atom or a carboxyl group-protecting group; R5 represents a hydrogen atom or a hydroxy group-protecting group). Alternatively, a salt thereof is provided.
C07D 215/56 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Provided is a blood pressure-lowering agent that is safe and has a relaxing effect. The active ingredient of the blood pressure-lowering agent is S-1-propenyl cysteine or a salt thereof.
Provided is an immunoregulator that is useful for modulating immune function and retaining homeostasis of a living body. The immunoregulator comprises as the active ingredient S-1-propenylcysteine or a salt thereof.
Provided is a compound useful as the active ingredient in a therapeutic drug composition for diseases that RANKL/RANK signals are involved in such as osteoporosis, osteopenia, and rheumatoid arthritis. The present inventors completed the present invention by investigating compounds having RANKL/RANK signal blocking activity, and confirming that a 2-(pyridine-2-yl)pyrimidine-4-amine compound or a salt thereof has RANKL/RANK signal blocking activity, ameliorates a RANKL-induced reduction in the mineral content of the bone, and is valid in an osteoporosis model and an arthritis model. The 2-(pyridine-2-yl)pyrimidine-4-amine compound or a salt thereof has RANKL/RANK signal blocking activity, and can be used as a therapeutic agent for diseases that RANKL/RANK signals are involved in, such as osteoporosis, osteopenia, and rheumatoid arthritis.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
A61P 19/10 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
The purpose of the invention is to provide a medicinal agent which has good solubility and good oxidative-stress-mediated cell death suppressing activity, can exhibit excellent blood-brain barrier penetration properties, and is effective for the treatment and prevention of neurological diseases. The invention provides: an acylaminoimidazole derivative represented by general formula (I) or a salt thereof; and a medicinal agent and a therapeutic or prophylactic agent for neurological diseases, each of which comprises the derivative or the salt thereof as an active ingredient.
A61K 31/4168 - 1,3-Diazoles having a nitrogen atom attached in position 2, e.g. clonidine
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
24.
PHOSPHATIDYLSERINE COMPLEX AND METHOD FOR STABILIZATION OF PHOSPHATIDYLSERINE
Disclosed are: a method which can stabilize phosphatidylserine conveniently and efficiently; and a phosphatidylserine complex having extremely excellent storage stability and producibility. Specifically disclosed are: a phosphatidylserine complex which is characterized by being produced by kneading phosphatidylserine with a dextrin; and a method for stabilizing phosphatidylserine, which is characterized by kneading phosphatidylserine with a dextrin. The dextrin comprises at least one member selected from the group consisting of a non-cyclic dextrin, a cyclodextrin and a highly-branched cyclic dextrin. The non-cyclic dextrin preferably has a weight average molecular weight of 500 to 120,000. It is preferred to knead 1 part by weight of phosphatidylserine with 0.5 to 20 parts by weight of the dextrin.
A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
Disclosed is an organolipid (a lipid occurring in an organ)-reducing agent and an alcohol metabolism promoter, each of which comprises, as an active ingredient, a composition produced by treating a ginseng in either one of the following steps (a) or (b) and further treating the treated ginseng in the other step: (a) contacting the ginseng with a microorganism or an enzyme; and (b) reacting the ginseng with an acid or an alkali. In the organolipid-reducing agent and the alcohol metabolism promoter, the step (a) may be a step of contacting the ginseng with an enzyme, and the step (b) may be a step of reacting the ginseng with an acid. In the organolipid-reducing agent and the alcohol metabolism promoter, the ginseng may be Tienchi ginseng. In the organolipid-reducing agent, the organ may be the liver. Also disclosed are a food and a pharmaceutical preparation both for reducing an organolipid, each of which comprises the organolipid-reducing agent. Further disclosed are a food and a pharmaceutical preparation both for promoting the alcohol metabolism, each of which comprises the alcohol metabolism promoter.
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
To provide an immunochromato device whereby both of the presence/absence of a target substance and the normal completion of a test can be confirmed in a determination section. An immunochromato device comprising a sample supply section, a development section and a determination section, characterized in that the development section holds a specifically bindable substance (or a target substance) carrying colored particles and a control substance carrying colored particles having a color tone differing from that of the former colored particles in a movable state, and the determination section has a substance capable of trapping the control substance that has been mixed with the target substance (or the specifically bindable substance) and solid-phased, or the target substance (or the specifically bindable substance) having a functional group capable of trapping the control substance introduced thereinto that has been solid-phased.
It is intended to provide an acidic liquid medicine containing a high concentration of a crude drug extract in which the occurrence of precipitation or suspension over time is suppressed. A vegetable crude drug extract-blended liquid medicine containing a vegetable crude drug extract in an amount of 5 to 50 w/v% (in terms of dry weight) based on the total amount of the liquid medicine and has a pH of 3.0 to 5.5, wherein a caramel which has an isoelectric point of 2.5 to 4.0 and has a pH of 4.5 to 6.0 in the case of a 1.0 w/v% aqueous solution thereof is contained in an amount of 0.5 to 20 w/v% based on the total amount of the liquid medicine. An animal crude drug extract-blended liquid medicine containing an animal crude drug extract in an amount of 5 to 50 w/v% (in terms of dry weight) based on the total amount of the liquid medicine and has a pH of 3.0 to 5.5, wherein a caramel which has an isoelectric point of 0.5 to 4.0 and has a pH of 4.5 to 6.1 in the case of a 1.0 w/v% aqueous solution thereof is contained in an amount of 0.5 to 20 w/v% based on the total amount of the liquid medicine.
Disclosed are a probe, a primer, a primer set, and an antibody which can be used for the determination on the occurrence or the risk of occurrence of neonatal alloimmune thrombocytopenic purpura. Specifically disclosed are a probe, a primer, a primer set and an antibody for use in the detection of a thymine residue at position-1297 on GPIIIa gene.
A compound represented by the formula (I): wherein R1 is lower alkyl, cycloalkyl or aromatic hydrocarbon ring, each of which is optionally substituted with one or more substituents; R2 is hydrogen atom, halogen atom, lower alkyl, halo(lower)alkyl or lower alkoxy; and R3 is (1) a group represented by the formula: wherein R4 is lower alkyl, etc.; (2) a group represented by the formula: wherein R5 is lower alkyl, etc.; (3) a group represented by the formula: wherein R6 is lower alkyl, etc.; or (4) a group selected from halogen atom, carboxy, hydroxy and lower alkoxy, or a salt thereof.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/4412 - Non-condensed pyridinesHydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
30.
IMMUNOLOGICAL DETECTION METHOD USING AVIAN ANTIBODY
Disclosed is an immunological detection method using an avian antibody, which involves the step of inhibiting any non-specific reaction resulted from the use of the avian antibody. Specifically disclosed is an immunological detection method comprising the step of detecting a substance of interest in a sample collected from a mammal by using an avail antibody, which is characterized by inhibiting any non-specific reaction resulted from the use of the avian antibody.
A tablet container has a container body for receiving tablets inside it and a film adhered to the opening or inner wall of the container body to seal the tablets. The air pressure of an inside air gap sealed by the film is maintained at a pressure lower than or equal to the air pressure outside the partitioning film. The tablet container can prevent breakage of the tablets by vibration and impact during transportation. Also, when a cushioning member is removed before a tablet is taken out from the container, tablets are less likely to fall out of the container. Also, the tablet container can be produced at relatively low cost and enables hygienic tablet handling.
B65D 81/02 - Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents specially adapted to protect contents from mechanical damage
A61J 1/03 - Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
B65B 61/00 - Auxiliary devices, not otherwise provided for, for operating on sheets, blanks, webs, binding material, containers or packages
The present invention provides a compound of the formula ⏧I]: wherein R1 is lower alkyl, etc. and R2 is hydrogen, etc., or R1 and R2 are bonded together to form lower alkylene; R3 is a group represented by wherein R6 and R7 are independently optionally protected amino, etc.; m and n are independently an integer of 0 to 6; R8 and R9 are independently optionally protected amino, etc., and q and r are independently an integer of 0 to 6, or R8 and R9, together with the adjacent alkylene(s) and the nitrogen atom, form saturated nitrogen-containing heterocycle optionally having substituent(s); R4 is lower alkyl, etc.; and R5 is amino, etc., or a pharmaceutically acceptable salt thereof.
C07D 501/46 - Methylene radicals, substituted by nitrogen atomsLactams thereof with the 2-carboxyl groupMethylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atomQuaternary compounds thereof with the 7-amino radical acylated by carboxylic acids containing hetero rings
A61K 31/546 - Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula , e.g. cephalosporins, cefaclor, cephalexine containing further heterocyclic rings, e.g. cephalothin
A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
33.
PANEL CELL USED FOR GRANULOCYTE ANTIBODY DETECTION
A panel cell for detecting an anti-HNA antibody is disclosed. This panel cell is obtained by introducing DNA encoding an HNA antigen responding to the anti-HNA antibody into a cell in an expressible form under a condition to be used for a detection operation and the cell before the introduction of the DNA does not show a response that can be detected by a detection operation with an anti-HLA-ABC antibody, an anti-HLA-DR antibody, an anti-HLA-DQ antibody, an anti-HLA-DP antibody, an anti-HNA-1 antibody, an anti-HNA-2a antibody, an anti-HNA-3a antibody, an anti-HNA-4 antibody, an anti-HNA-5 antibody and serum from a healthy subject. By using the panel cell, accurate and rapid detection of a granulocyte antibody becomes possible.
G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
34.
METHOD FOR PRODUCING PHOSPHOLIPID CONTAINING POLYVALENT UNSATURATED FATTY ACID, AND PHOSPHOLIPID CONTAINING POLYVALENT UNSATURATED FATTY ACID OBTAINED BY SUCH METHOD
Disclosed is a method for producing a phospholipid containing a polyvalent unsaturated fatty acid in a two-phase system, wherein the yield of the produced phospholipid is high, isolation of the product is easy, and oxidation of the polyvalent unsaturated fatty acid is suppressed. Specifically disclosed is a method for producing a phospholipid containing a polyvalent unsaturated fatty acid, which is characterized by comprising a step wherein a phospholipid containing a polyvalent unsaturated fatty acid and a hydroxyl group-containing compound are reacted in a two-phase system composed of a nonpolar solvent, a polar solvent and water in the presence of an antioxidant and phospholipase D. This method for producing a phospholipid containing a polyvalent unsaturated fatty acid is further characterized in that the polar solvent content relative to the total of the nonpolar solvent and the polar solvent is more than 20% but not more than 80% on a volume basis, and the molar ratio of the hydroxyl group-containing compound to the phospholipid is not less than 4 but not more than 30.
